{
    "clinical_study": {
        "@rank": "107537", 
        "arm_group": {
            "arm_group_label": "Cefazolin", 
            "arm_group_type": "Other", 
            "description": "Cefazolin used in antimicrobial prophylaxis\nCefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.\nTwo samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.\nThe samples were processed by High Pressure Liquid Chromatography (HPLC)."
        }, 
        "brief_summary": {
            "textblock": "Eighteen patients were given a dose of 2g Cefazolin in anesthetic induction, supplemented\n      with 1g delivered through continuous infusion during surgery. Adipose samples, obtained at\n      the beginning and end of surgery, were analyzed using high performance liquid\n      chromatography.\n\n      Some published studies suggest that the dose of 2g does not supply the minimum inhibitory\n      concentration for principal causal agents of surgical site infection.\n\n      To determine the concentration of Cefazolin in adipose tissue of patients undergoing\n      bariatric surgery and to evaluate the relationship between concentrations obtained and body\n      mass index (BMI)."
        }, 
        "brief_title": "Antibiotic Prophylaxis in Bariatric Surgery With Cefazolin: Concentration in Adipose Tissue", 
        "completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  body mass index greater than 35 and less than 50kg/m2\n\n        Exclusion Criteria:\n\n          -  Hypotension during surgery with use of vasoactive drugs\n\n          -  renal disfunction (creatinine >1.5 mg/dL)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845363", 
            "org_study_id": "Cefa01"
        }, 
        "intervention": {
            "arm_group_label": "Cefazolin", 
            "description": "Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.\nTwo samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.\nThe samples were processed by HPLC.", 
            "intervention_name": "Cefazolin used in antimicrobial prophylaxis", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Infective Agents", 
                "Cefazolin", 
                "Anti-Bacterial Agents", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Obesity", 
            "Bariatric surgery", 
            "Cefazolin", 
            "antimicrobial prophylaxis", 
            "administration and dosage"
        ], 
        "lastchanged_date": "April 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Recife", 
                    "country": "Brazil", 
                    "state": "Pernambuco", 
                    "zip": "50670901"
                }, 
                "name": "Universidade Federal de Pernambuco - Hospital das Cl\u00ednicas"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "Antibiotic Prophylaxis in Bariatric Surgery With Continuous Infusion of Cefazolin: Determination of Concentration in Adipose Tissue", 
        "overall_official": [
            {
                "affiliation": "UFPE", 
                "last_name": "Rafael Anlicoara, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "UFPE - Hospital das Cl\u00ednicas", 
                "last_name": "Alvaro AB Ferraz, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Laboratory of Immunopathology Keiso Asami(LIKA) - UFPE", 
                "last_name": "Jos\u00e9 L de Lima Filho, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "dosage of Cefazolin in adipose tissue during bariatric surgery", 
            "safety_issue": "No", 
            "time_frame": "eight months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845363"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universidade Federal de Pernambuco", 
            "investigator_full_name": "Rafael Anlicoara", 
            "investigator_title": "Master\u00b4s degree", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Universidade Federal de Pernambuco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universidade Federal de Pernambuco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}